We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIV

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00256828
Recruitment Status : Completed
First Posted : November 22, 2005
Last Update Posted : October 16, 2007
Information provided by:
Clinical Trial Agency of HIV Study Group